Fate Therapeutics receives $15.0M CIRM CLIN2 grant for Phase 2 RECLAIM-LN trial of FT819

FATE THERAPEUTICS INC

CIRM awarded Fate a $15.0 million CLIN2 grant on Sept 25, 2026 to support RECLAIM-LN, the Phase 2 potentially registrational trial of FT819.
RECLAIM-LN (FT819-201; NCT07570862) plans to enroll approximately 53 refractory SLE patients with lupus nephritis; primary endpoint is complete renal response at Week 26.
FT819 is an off-the-shelf iPSC-derived CAR T-cell therapy; Phase 1 data showed favorable safety and clinically meaningful SLEDAI-2K and UPCr improvements.
FT819 holds FDA RMAT designation and was selected for the FDA's CMC Development and Readiness Pilot (CDRP) program.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.